I'm LongbridgeAI, I can summarize articles.Livzon Pharmaceutical Group ( (HK:1513) ) has provided an update.
Livzon Pharmaceutical Group has announced that Mr. Xu Xiao has resigned from his role as vice president due to work adjustments, though he will remain in other positions within the company. The board emphasized that the move will not affect the company’s normal operations, noted that Mr. Xu holds no shares, and expressed appreciation for his diligent service.
The company also reaffirmed the current composition of its board, which includes executive, non-executive, employee representative and independent non-executive directors, underscoring continuity in overall governance. By clarifying that there are no disagreements related to the resignation and no issues requiring shareholder attention, Livzon sought to reassure investors about management stability and ongoing corporate oversight.
The most recent analyst rating on (HK:1513) stock is a Sell
with a HK$22.99 price target.
To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock,
see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company focused on the research, development, manufacturing and sale of medicines and related healthcare products. The group operates through multiple subsidiaries and is listed in Hong Kong, giving it access to international capital markets and a broad base of institutional and retail investors.
Average Trading Volume: 1,206,622
Technical Sentiment Signal: Sell
Current Market Cap: HK$24.62B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.